Trinity Biotech (TRIB) received an order for 9M units of its flagship HIV screening product, TrinScreen HIV. Trinity Biotech will produce the tests through its recently WHO-approved outsourced manufacturing process, which allows for efficient and cost-effective scalability. The company anticipates fulfilling the order during the fourth quarter of 2025 and the first quarter of 2026.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech Accelerates Global Rollout of High-Capacity HbA1c Column System After New Regulatory Clearances
- Trinity Biotech expands global rollout of high-capacity column system
- Trinity Biotech Secures WHO Approval for Offshore Manufacturing of HIV Test
- Trinity Biotech Collaborates to Enhance Prostate Cancer Test
- Trinity Biotech secures regulatory approval for outsourced manufacturing